321 related articles for article (PubMed ID: 24656406)
1. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients.
Cheung YT; Foo YL; Shwe M; Tan YP; Fan G; Yong WS; Madhukumar P; Ooi WS; Chay WY; Dent RA; Ang SF; Lo SK; Yap YS; Ng R; Chan A
J Clin Epidemiol; 2014 Jul; 67(7):811-20. PubMed ID: 24656406
[TBL] [Abstract][Full Text] [Related]
2. Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients.
Chan A; Yo TE; Wang XJ; Ng T; Chae JW; Yeo HL; Shwe M; Gan YX
J Pain Symptom Manage; 2018 Mar; 55(3):992-997.e2. PubMed ID: 29097274
[TBL] [Abstract][Full Text] [Related]
3. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
[TBL] [Abstract][Full Text] [Related]
4. Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy.
Raman S; Ding K; Chow E; Meyer RM; Nabid A; Chabot P; Coulombe G; Ahmed S; Kuk J; Dar AR; Mahmud A; Fairchild A; Wilson CF; Wu JSY; Dennis K; DeAngelis C; Wong RKS; Zhu L; Brundage M
Qual Life Res; 2016 Oct; 25(10):2535-2541. PubMed ID: 27138964
[TBL] [Abstract][Full Text] [Related]
5. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
[TBL] [Abstract][Full Text] [Related]
6. The psychometric properties of the Korean version of the functional assessment of cancer therapy-cognitive (FACT-Cog) in Korean patients with breast cancer.
Park JH; Bae SH; Jung YS; Jung YM
Support Care Cancer; 2015 Sep; 23(9):2695-703. PubMed ID: 25666997
[TBL] [Abstract][Full Text] [Related]
7. What Are the Minimum Clinically Important Differences in SF-36 Scores in Patients with Orthopaedic Oncologic Conditions?
Ogura K; Yakoub MA; Christ AB; Fujiwara T; Nikolic Z; Boland PJ; Healey JH
Clin Orthop Relat Res; 2020 Sep; 478(9):2148-2158. PubMed ID: 32568896
[TBL] [Abstract][Full Text] [Related]
8. Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy.
Hong F; Bosco JL; Bush N; Berry DL
BMC Cancer; 2013 Mar; 13():165. PubMed ID: 23537330
[TBL] [Abstract][Full Text] [Related]
9. Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases.
Wong E; Zhang L; Kerba M; Arnalot PF; Danielson B; Tsao M; Bedard G; Thavarajah N; Cheon P; Danjoux C; Pulenzas N; Chow E
Support Care Cancer; 2015 Sep; 23(9):2731-7. PubMed ID: 25663577
[TBL] [Abstract][Full Text] [Related]
10. Psychometric properties and measurement equivalence of the English and Chinese versions of the functional assessment of cancer therapy-cognitive in Asian patients with breast cancer.
Cheung YT; Lim SR; Shwe M; Tan YP; Chan A
Value Health; 2013; 16(6):1001-13. PubMed ID: 24041350
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.
Janelsins MC; Heckler CE; Peppone LJ; Kamen C; Mustian KM; Mohile SG; Magnuson A; Kleckner IR; Guido JJ; Young KL; Conlin AK; Weiselberg LR; Mitchell JW; Ambrosone CA; Ahles TA; Morrow GR
J Clin Oncol; 2017 Feb; 35(5):506-514. PubMed ID: 28029304
[TBL] [Abstract][Full Text] [Related]
12. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
Maringwa J; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Reeve BB; Gotay C; Greimel E; Flechtner H; Cleeland CS; Schmucker-Von Koch J; Weis J; Van Den Bent MJ; Stupp R; Taphoorn MJ; Bottomley A;
Ann Oncol; 2011 Sep; 22(9):2107-2112. PubMed ID: 21324954
[TBL] [Abstract][Full Text] [Related]
13. An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases.
Zeng L; Chow E; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Bedard G; Bottomley A
Support Care Cancer; 2012 Dec; 20(12):3307-13. PubMed ID: 22562607
[TBL] [Abstract][Full Text] [Related]
14. Screening for cognitive symptoms among cancer patients during chemotherapy: Sensitivity and specificity of a single item self-report cognitive change score.
Fardell JE; Bray V; Bell ML; Rabe B; Dhillon H; Vardy JL
Psychooncology; 2022 Aug; 31(8):1294-1301. PubMed ID: 35320617
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G; Holzner B; Kopp M; Dünser M; Margreiter R; Greil R; Sperner-Unterweger B
J Clin Oncol; 1999 Sep; 17(9):2932-40. PubMed ID: 10561373
[TBL] [Abstract][Full Text] [Related]
16. Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population.
Oliveira AF; Santos IM; Fernandes S; Bem-Haja P; Torres A
BMC Psychol; 2022 Dec; 10(1):305. PubMed ID: 36517827
[TBL] [Abstract][Full Text] [Related]
17. The quality of spine surgery from the patient's perspective: part 2. Minimal clinically important difference for improvement and deterioration as measured with the Core Outcome Measures Index.
Mannion AF; Porchet F; Kleinstück FS; Lattig F; Jeszenszky D; Bartanusz V; Dvorak J; Grob D
Eur Spine J; 2009 Aug; 18 Suppl 3(Suppl 3):374-9. PubMed ID: 19296136
[TBL] [Abstract][Full Text] [Related]
18. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients.
Cheung YT; Shwe M; Chui WK; Chay WY; Ang SF; Dent RA; Yap YS; Lo SK; Ng RC; Chan A
Ann Pharmacother; 2012 Dec; 46(12):1645-55. PubMed ID: 23249868
[TBL] [Abstract][Full Text] [Related]
19. Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change.
Luckett T; King M; Butow P; Friedlander M; Paris T
Int J Gynecol Cancer; 2010 May; 20(4):664-84. PubMed ID: 20442592
[TBL] [Abstract][Full Text] [Related]
20. The minimal clinically important difference in the treadmill six-minute walk test in active women with breast cancer during and after oncological treatments.
Cantarero-Villanueva I; Postigo-Martin P; Granger CL; Waterland J; Galiano-Castillo N; Denehy L
Disabil Rehabil; 2023 Mar; 45(5):871-878. PubMed ID: 35352996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
